Trial of CF101 to Treat Patients With Psoriasis

Inclusion Criteria: * Male or female, 18 to 80 years of age, inclusive * Diagnosis of moderate-to-severe chronic plaque-type psoriasis with body surface area involvement ≥10% * Duration of psoriasis of at least 6 months * Physician global assessment (PGA) ≥3 * Candidate for systemic treatment or phototherapy for psoriasis * Electrocardiogram (ECG) is normal * Females of child-bearing potential must have a negative serum pregnancy test * Females of child-bearing potential must be willing to use 2 methods of contraception * Ability to complete the study in compliance with the protocol * Ability to understand and provide written informed consent. Exclusion Criteria: * Erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis * Treatment with systemic retinoids, corticosteroids, or immunosuppressive agents within 4 weeks of the Baseline visit * Treatment with high potency topical corticosteroids, keratolytics, or coal tar within 2 weeks of the Baseline visit * Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit * Treatment with a biological agent within a period of time equal to 5 times its circulating half-life * Treatment with lithium, hydroxychloroquine or chloroquine within 2 weeks of the Baseline visit * Serum creatinine level greater than 1.5 times the laboratory's upper limit of normal * Liver aminotransferase levels greater than the laboratory's upper limit of normal * Significant acute or chronic medical or psychiatric illness * Participation in another investigational drug or vaccine trial concurrently or within 30 days prior to Screening visit.